BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 35640920)

  • 1. Activation of Hedgehog signaling by the oncogenic RELA fusion reveals a primary cilia-dependent vulnerability in supratentorial ependymoma.
    de Almeida Magalhães T; Alencastro Veiga Cruzeiro G; Ribeiro de Sousa G; Englinger B; Fernando Peinado Nagano L; Ancliffe M; Rodrigues da Silva K; Jiang L; Gojo J; Cherry Liu Y; Carline B; Kuchibhotla M; Pinto Saggioro F; Kazue Nagahashi Marie S; Mieko Oba-Shinjo S; Andres Yunes J; Gomes de Paula Queiroz R; Alberto Scrideli C; Endersby R; Filbin MG; Silva Borges K; Salic A; Gonzaga Tone L; Valera ET
    Neuro Oncol; 2023 Jan; 25(1):185-198. PubMed ID: 35640920
    [TBL] [Abstract][Full Text] [Related]  

  • 2. C11orf95-RELA fusions and upregulated NF-KB signalling characterise a subset of aggressive supratentorial ependymomas that express L1CAM and nestin.
    Malgulwar PB; Nambirajan A; Pathak P; Faruq M; Rajeshwari M; Singh M; Suri V; Sarkar C; Sharma MC
    J Neurooncol; 2018 May; 138(1):29-39. PubMed ID: 29354850
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MRI Phenotype of RELA-fused Pediatric Supratentorial Ependymoma.
    Nowak J; Jünger ST; Huflage H; Seidel C; Hohm A; Vandergrift LA; von Hoff K; Rutkowski S; Pietsch T; Warmuth-Metz M
    Clin Neuroradiol; 2019 Dec; 29(4):595-604. PubMed ID: 30027327
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinicopathological evaluation of PD-L1 expression and cytotoxic T-lymphocyte infiltrates across intracranial molecular subgroups of ependymomas: are these tumors potential candidates for immune check-point blockade?
    Nambirajan A; Malgulwar PB; Sharma A; Boorgula MT; Doddamani R; Singh M; Suri V; Sarkar C; Sharma MC
    Brain Tumor Pathol; 2019 Oct; 36(4):152-161. PubMed ID: 31388782
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Specific expression of PD-L1 in RELA-fusion supratentorial ependymoma: Implications for PD-1-targeted therapy.
    Witt DA; Donson AM; Amani V; Moreira DC; Sanford B; Hoffman LM; Handler MH; Levy JMM; Jones KL; Nellan A; Foreman NK; Griesinger AM
    Pediatr Blood Cancer; 2018 May; 65(5):e26960. PubMed ID: 29350470
    [TBL] [Abstract][Full Text] [Related]  

  • 6. C11orf95-RELA reprograms 3D epigenome in supratentorial ependymoma.
    Zhu JJ; Jillette N; Li XN; Cheng AW; Lau CC
    Acta Neuropathol; 2020 Dec; 140(6):951-960. PubMed ID: 32909151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. L1CAM Immunopositivity in Anaplastic Supratentorial Ependymomas: Correlation With Clinical and Histological Parameters.
    Chavali P; Rao S; Palavalasa S; Bevinahalli N; Muthane YTC; Sadashiva N; Santosh V
    Int J Surg Pathol; 2019 May; 27(3):251-258. PubMed ID: 30251576
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Supratentorial ependymoma in childhood: more than just RELA or YAP.
    Zschernack V; Jünger ST; Mynarek M; Rutkowski S; Garre ML; Ebinger M; Neu M; Faber J; Erdlenbruch B; Claviez A; Bielack S; Brozou T; Frühwald MC; Dörner E; Dreschmann V; Stock A; Solymosi L; Hench J; Frank S; Vokuhl C; Waha A; Andreiuolo F; Pietsch T
    Acta Neuropathol; 2021 Mar; 141(3):455-466. PubMed ID: 33481105
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Supratentorial non-RELA, ZFTA-fused ependymomas: a comprehensive phenotype genotype correlation highlighting the number of zinc fingers in ZFTA-NCOA1/2 fusions.
    Tauziède-Espariat A; Siegfried A; Nicaise Y; Kergrohen T; Sievers P; Vasiljevic A; Roux A; Dezamis E; Benevello C; Machet MC; Michalak S; Puiseux C; Llamas-Gutierrez F; Leblond P; Bourdeaut F; Grill J; Dufour C; Guerrini-Rousseau L; Abbou S; Dangouloff-Ros V; Boddaert N; Saffroy R; Hasty L; Wahler E; Pagès M; Andreiuolo F; Lechapt E; Chrétien F; Blauwblomme T; Beccaria K; Pallud J; Puget S; Uro-Coste E; Varlet P;
    Acta Neuropathol Commun; 2021 Aug; 9(1):135. PubMed ID: 34389065
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Significance of molecular classification of ependymomas: C11orf95-RELA fusion-negative supratentorial ependymomas are a heterogeneous group of tumors.
    Fukuoka K; Kanemura Y; Shofuda T; Fukushima S; Yamashita S; Narushima D; Kato M; Honda-Kitahara M; Ichikawa H; Kohno T; Sasaki A; Hirato J; Hirose T; Komori T; Satomi K; Yoshida A; Yamasaki K; Nakano Y; Takada A; Nakamura T; Takami H; Matsushita Y; Suzuki T; Nakamura H; Makino K; Sonoda Y; Saito R; Tominaga T; Matsusaka Y; Kobayashi K; Nagane M; Furuta T; Nakada M; Narita Y; Hirose Y; Ohba S; Wada A; Shimizu K; Kurozumi K; Date I; Fukai J; Miyairi Y; Kagawa N; Kawamura A; Yoshida M; Nishida N; Wataya T; Yamaoka M; Tsuyuguchi N; Uda T; Takahashi M; Nakano Y; Akai T; Izumoto S; Nonaka M; Yoshifuji K; Kodama Y; Mano M; Ozawa T; Ramaswamy V; Taylor MD; Ushijima T; Shibui S; Yamasaki M; Arai H; Sakamoto H; Nishikawa R; Ichimura K;
    Acta Neuropathol Commun; 2018 Dec; 6(1):134. PubMed ID: 30514397
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Notch pathway in ependymoma RELA-fused subgroup: upregulation and association with cancer stem cells markers expression.
    de Almeida Magalhães T; Cruzeiro GAV; de Sousa GR; da Silva KR; Lira RCP; Scrideli CA; Tone LG; Valera ET; Borges KS
    Cancer Gene Ther; 2020 Jun; 27(6):509-512. PubMed ID: 31308481
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel type of C11orf95-LOC-RELA fusion in a grade II supratentorial ependymoma: report of a case with literature review.
    de Sousa GR; Marie SKN; Oba-Shinjo SM; Ramalho LNZ; Tone LG; Valera ET
    Childs Nerv Syst; 2019 Apr; 35(4):689-694. PubMed ID: 30631904
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Encouraging option of multi-staged gross total resection for a C11orf-RelA fusion-positive supratentorial anaplastic ependymoma.
    Nakamura T; Fukuoka K; Ikeda J; Yoshitomi M; Udaka N; Tanoshima R; Tateishi K; Yamanaka S; Ichimura K; Yamamoto T
    Brain Tumor Pathol; 2017 Oct; 34(4):160-164. PubMed ID: 28831588
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of Immunohistochemistry in the Identification of Supratentorial C11ORF95-RELA Fused Ependymoma in Routine Neuropathology.
    Gessi M; Giagnacovo M; Modena P; Elefante G; Gianno F; Buttarelli FR; Arcella A; Donofrio V; Diomedi Camassei F; Nozza P; Morra I; Massimino M; Pollo B; Giangaspero F; Antonelli M
    Am J Surg Pathol; 2019 Jan; 43(1):56-63. PubMed ID: 29266023
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostics of pediatric supratentorial RELA ependymomas: integration of information from histopathology, genetics, DNA methylation and imaging.
    Pagès M; Pajtler KW; Puget S; Castel D; Boddaert N; Tauziède-Espariat A; Picot S; Debily MA; Kool M; Capper D; Sainte-Rose C; Chrétien F; Pfister SM; Pietsch T; Grill J; Varlet P; Andreiuolo F
    Brain Pathol; 2019 May; 29(3):325-335. PubMed ID: 30325077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Review of ependymomas: assessment of consensus in pathological diagnosis and correlations with genetic profiles and outcome.
    Sasaki A; Hirato J; Hirose T; Fukuoka K; Kanemura Y; Hashimoto N; Kodama Y; Ichimura K; Sakamoto H; Nishikawa R
    Brain Tumor Pathol; 2019 Apr; 36(2):92-101. PubMed ID: 30929114
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low-dose Actinomycin-D treatment re-establishes the tumoursuppressive function of P53 in RELA-positive ependymoma.
    Tzaridis T; Milde T; Pajtler KW; Bender S; Jones DT; Müller S; Wittmann A; Schlotter M; Kulozik AE; Lichter P; Peter Collins V; Witt O; Kool M; Korshunov A; Pfister SM; Witt H
    Oncotarget; 2016 Sep; 7(38):61860-61873. PubMed ID: 27556362
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A coordinated approach for the assessment of molecular subgroups in pediatric ependymomas using low-cost methods.
    de Sousa GR; Lira RCP; de Almeida Magalhães T; da Silva KR; Nagano LFP; Saggioro FP; Baroni M; Marie SKN; Oba-Shinjo SM; Brandelise S; de Paula Queiroz RG; Brassesco MS; Scrideli CA; Tone LG; Valera ET
    J Mol Med (Berl); 2021 Aug; 99(8):1101-1113. PubMed ID: 33903940
    [TBL] [Abstract][Full Text] [Related]  

  • 19. epi-Aszonalenin B from Aspergillus novofumigatus inhibits NF-κB activity induced by ZFTA-RELA fusion protein that drives ependymoma.
    Ishikawa K; Ishii M; Yaguchi T; Katada T; Ichinose K; Ohata S
    Biochem Biophys Res Commun; 2022 Mar; 596():104-110. PubMed ID: 35131506
    [TBL] [Abstract][Full Text] [Related]  

  • 20. C11orf95-RELA fusion drives aberrant gene expression through the unique epigenetic regulation for ependymoma formation.
    Ozawa T; Kaneko S; Szulzewsky F; Qiao Z; Takadera M; Narita Y; Kondo T; Holland EC; Hamamoto R; Ichimura K
    Acta Neuropathol Commun; 2021 Mar; 9(1):36. PubMed ID: 33685520
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.